- Report
- February 2024
- 250 Pages
Global
From €4834EUR$5,000USD£4,155GBP
- Report
- February 2024
- 250 Pages
Global
From €4834EUR$5,000USD£4,155GBP
- Report
- February 2024
- 250 Pages
Global
From €4834EUR$5,000USD£4,155GBP
- Report
- January 2024
- 200 Pages
Global
From €4834EUR$5,000USD£4,155GBP
- Report
- January 2024
- 200 Pages
Global
From €4834EUR$5,000USD£4,155GBP
- Report
- October 2023
- 150 Pages
Global
From €4689EUR$4,850USD£4,030GBP
- Report
- April 2024
- 193 Pages
Global
From €5414EUR$5,600USD£4,653GBP
- Report
- March 2024
- 145 Pages
Global
From €3769EUR$3,899USD£3,240GBP
- Report
- July 2023
- 143 Pages
Global
From €2416EUR$2,499USD£2,076GBP
- Report
- September 2023
- 76 Pages
Global
From €4785EUR$4,950USD£4,113GBP
- Report
- February 2024
- 116 Pages
Global
From €4592EUR$4,750USD£3,947GBP
- Report
- April 2024
- 187 Pages
Global
From €4737EUR$4,900USD£4,071GBP
- Report
- October 2023
- 178 Pages
Global
From €4737EUR$4,900USD£4,071GBP
- Report
- October 2023
- 189 Pages
Global
From €4737EUR$4,900USD£4,071GBP
- Report
- April 2024
- 1130 Pages
Global
From €1204EUR$1,289USD£1,000GBP
- Report
- March 2024
- 200 Pages
Global
From €4012EUR$4,150USD£3,448GBP
- Report
- March 2024
- 118 Pages
Global
From €4350EUR$4,500USD£3,739GBP
- Report
- December 2023
- 76 Pages
Global
From €7729EUR$7,995USD£6,643GBP
- Report
- January 2024
- 242 Pages
Global
€4829EUR$4,995USD£4,150GBP
- Report
- January 2024
- 250 Pages
Global
€4829EUR$4,995USD£4,150GBP
The Biosimilars and Biosuperiors market is a rapidly growing sector of the pharmaceutical industry. Biosimilars are biologic drugs that are highly similar to an existing biologic drug, while biosuperiors are biologic drugs that are more effective than an existing biologic drug. Biosimilars and biosuperiors are used to treat a variety of conditions, including cancer, autoimmune diseases, and inflammatory diseases.
Biosimilars and biosuperiors are developed using advanced biotechnology techniques, such as recombinant DNA technology and monoclonal antibody technology. These drugs are designed to be more cost-effective than their original counterparts, while still providing the same therapeutic benefits.
The Biosimilars and Biosuperiors market is expected to continue to grow in the coming years, as more biologic drugs are developed and approved for use. Companies in this market include Amgen, Pfizer, Merck, and Novartis. Show Less Read more